26.02.2021 – 06:18
Jubilant Therapeutics Inc.
Bedminster, New Jersey (ots/PRNewswire)
Jubilant Therapeutics Inc. , a biopharmaceutical company developing small molecule modulators to meet unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with the Boston Children’s Hospital known to evaluate peptidyl arginine deiminase 4 (PAD4) inhibitors being developed by Jubilant Therapeutics to study the modulation of neutrophil extracellular traps (NETosis) in preclinical models of neutrophil regulation and rheumatoid arthritis (RA).
PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils. Histone citrullination has been linked to the formation of NETs, which are believed to contribute to pro-inflammation and disease progression in many autoimmune diseases such as RA, fibrosis, lupus, and ARDS.
“We are pleased to announce our collaboration with Boston Children’s Hospital, whose reputation as the nation’s leading pediatric hospital and research company makes them an ideal partner in developing the next generation of therapeutics for autoimmune diseases,” said Syed Kazmi, president and Chief Executive Officer of Jubilant Therapeutics. “Dr. Denisa Wagner, the lead investigator, has extensive experience in both PAD4 and the role of NETs in pathological inflammation and we are thrilled to have her on the team,” he added.
“My laboratory is convinced that PAD4-mediated NET formation contributes significantly to many inflammatory and thrombotic diseases. We have concluded this from our work with PAD4-deficient mice. Specific PAD4 inhibitors that are well tolerated by animals, would be great for pre-clinical and post-human studies. We look forward to testing Jubilant Therapeutics’ inhibitors on isolated neutrophils and later on mouse models of RA that we have established in our laboratory, “said Denisa Wagner, Ph.D., Senior Investigator, Program in Cellular and Molecular Medicine, and Edwin Cohn Professor of Pediatrics, Harvard Medical School.
Boston Children’s Hospital information
The Boston Children’s Hospital is recognized by the US News & World Report as that Children’s Hospital No. 1 rated in the nation and is the primary pediatric teaching institution of Harvard Medical School. It is home to the world’s largest research company, based at a pediatric medical center, whose discoveries have benefited both children and adults since 1869. Today, 3,000 researchers and academic staff, including 8 members of the National Academy of Sciences, 21 members of the National Academy of Medicine, and 12 Howard Hughes Medical Investigators make up the Boston Children’s research community. Visit our DiscoveriesBlog and follow us on social media 125> @BostonChildrens, @BCH_Innovation, Facebook and YouTube.
About Jubilant Therapeutics
Jubilant Therapeutics Inc. is a patient-focused biopharmaceutical company developing effective and selective small molecule modulators to meet medical needs in oncology and autoimmune diseases. Its advanced research strategy integrates structure-based design and computational algorithms to discover and develop novel, precise therapeutics that target both early targets of their kind and validated but persistent targets in genetically defined patient populations. The company’s entrepreneurial leadership and academic teams strive for speed and efficiency by applying a business model that leverages the proven and synergistic capabilities of the value chain and shared services of Jubilant Life Sciences Limited. Jubilant Therapeutics is headquartered in the United States and is led by globally recognized opinion leaders and members of the Scientific Advisory Board. You can find more information on www.jubilanttx.com or follow us on Twitter @JubilantTx or LinkedIn.
Boston Children’s Hospital Media Contact: Bethany Tripp
Original content by: Jubilant Therapeutics Inc., transmitted by news aktuell